Pilot Acute Safety Evaluation of Innocell™ Cancer Immunotherapy in Canine Subjects.

Raymond P GoodrichJon WestonLindsay HartsonLynn GriffinAmanda Guth

Published in: Journal of immunology research (2020)

Subcutaneous injection of the inactivated tumor cells and adjuvant was well tolerated in this pilot study. Cytokine responses observed were in line with the intended use of the treatment in stimulating immune response without adverse clinical observations. Additional evaluation is warranted.

Keyphrases

immune response
liver failure
early stage
respiratory failure
drug induced
toll like receptor
dendritic cells
clinical trial
emergency department
intensive care unit
ultrasound guided
aortic dissection
combination therapy
adverse drug
double blind
smoking cessation